GlassScriptPhysician profile
Latisha A Ali
NPI 1295217198
$15,027.03
in general payments reported to CMS, 2019-2025
27 companies · $2,918 in 2025
The $2,918 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,257 · 2022: $3,555 · 2023: $3,260 · 2024: $3,037 · 2025: $2,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,215.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,427.84 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,949.25 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,497.89 | 2021-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $1,445.24 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,443.88 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $1,224.59 | 2021-2025 | Trintellix |
| Alkermes, INC. | $953.23 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $817.79 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $682.37 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Lundbeck LLC | $571.16 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $484.57 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $339.36 | 2022-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $318.42 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Avanir Pharmaceuticals, INC. | $151.87 | 2022 | |
| Sunovion Pharmaceuticals INC. | $140.78 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $112.63 | 2022-2023 | Azstarys |
| Bausch Health US, LLC | $101.31 | 2022-2023 | Aplenzin |
| Neos Therapeutics, LP | $94.05 | 2021-2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $64.46 | 2023-2024 | Xelstrym, Secuado |
| Indivior INC. | $41.28 | 2021 | |
| Idorsia Pharmaceuticals US INC | $33.78 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $29.84 | 2024 | |
| Eisai INC. | $28.82 | 2021 | |
| Adlon Therapeutics L.P. | $26.73 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.36 | 2025 | Rejoyn |
| E.R. Squibb & Sons, L.L.C. | $16.15 | 2024 | Cobenfy |
| Tris Pharma INC | $13.38 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latisha Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.